Navigation Links
MD Anderson and Biocept Scientists to Present Poster at ASCO on Disseminated Tumor Cells (DTCs) in Bone Marrow and Circulating Tumor Cells (CTCs) in Blood in Early Stage Breast Cancer Patients
Date:6/2/2011

SAN DIEGO, June 2, 2011 /PRNewswire/ -- Data to be presented in a poster at the 2011 Annual Meeting of the American Society of Clinical Oncology (ASCO) taking place in Chicago, Illinois June 3-7 by researchers from The University of Texas MD Anderson Cancer Center and Biocept, Inc. show that a laboratory test developed by Biocept, Inc. for the evaluation of HER2 status of Circulating Tumor Cells (CTCs) and Disseminated Tumor Cells (DTCs) can provide potentially valuable information to physicians treating breast cancer patients, different from that obtained through analysis of surgical resections.

The study involved 50 breast cancer patients from The University of Texas MD Anderson Cancer Center, most with early stage operable disease, from whom tumor tissue, bone marrow and blood samples were obtained.  DTCs and CTCs isolated from the bone marrow and blood samples with Biocept's OncoCEE technology, respectively, were tested for Human Epidermal growth factor Receptor-2 (HER2) by fluorescence in situ hybridization (FISH), and the results compared.  Typically, 20-25% of breast cancer patients are determined to be HER2 positive, by FISH or immunohistochemistry (IHC).

"This research builds on collaborative work between MD Anderson and Biocept focused on exploring the utility of testing CTCs and DTCs in conjunction with tumor tissue from surgical biopsies of breast cancer patients for biomarkers like HER2," said Anthony Lucci, MD., Professor, Department of Surgical Oncology, Division of Surgery at MD Anderson.  "We found in a number of cases discordance of HER2 status between primary tumors and CTCs or DTCs.  Specifically, HER2 positive CTCs and DTCs were found in a significant number of patients with HER2 negative primary tumors. Since HER2 was analyzed by FISH, we feel the testing is rigorous. This pilot study supports the need for further characterization of markers on DTCs and CTCs as a means of personalizing targeted therapies for breast cancer."

Additional details for the ASCO poster are as follows:
Mon, June 6, 1:00 PM – 5:00 PM (5:00 PM: Hall A, poster #10G)
Abstract #613 - Detection of HER2 status of circulating tumor cells and disseminated tumor cells using a microfluidic platform (cell enrichment and extraction technology [CEE]).
S. Krishnamurthy, F. Z. Bischoff, J. A. Mayer, K. Wong, S. Mikolajczyk, T. Pham, H. M. Kuerer, A. Lodhi, A. Bhattacharyya, C. Hall, A. Lucci Jr.; University of Texas M. D. Anderson Cancer Center, Houston, TX; Biocept, Inc., San Diego, CA

The abstract is available and can be viewed on-line at no charge through the ASCO website at http://www.asco.org.

About Biocept, Inc.

Biocept Laboratories, headquartered in San Diego, California, is an advanced CLIA-certifed laboratory services company specializing in the capture, detection, enumeration and analysis of Circulating Tumor Cells (CTCs).  Biocept's mission is to enhance the lives of cancer patients through the development of innovative diagnostic products and services.   Biocept utilizes innovative, proprietary technologies to deliver clinically relevant and actionable information to physicians that enable better patient care.  This includes clinical assessments of CTCs, both prognostic and predictive, which may provide physicians with important information for the treatment of their patients with cancer.

About OncoCEE™

The OncoCEE™ platform, developed by Biocept, has demonstrated that it can consistently and accurately capture extremely rare cells, like CTCs, which may be present in only 1 of every 50-100 billion blood cells.  Biocept obtains patient samples via a simple blood draw, or "liquid biopsy", instead on relying on traditional biopsy methods or surgical procedures.  Existing methods to detect and enumerate CTCs rely only on the expression of epithelial cell adhesion molecule (EpCAM) and cytokeratins.  This limited selection may exclude cells that have undergone intrinsic modifications of their phenotype such as epithelial/mesenchymal transition (EMT).   EMT may represent a possible explanation for patients who, despite an aggressive disease, are found negative for the presence of CTCs.  Because it employs an antibody cocktail, OncoCEE™ has the potential to capture not only EpCAM but also mesenchymal-like cells.  Additionally, OncoCEE™ enables in situ analysis of predictive biomarkers like HER2 estrogen receptor (ER) and  progesterone receptor (PR).

For more information, please visit Biocept’s web site at http://www.biocept.com . The Company’s website is not part of this press release.


'/>"/>
SOURCE Biocept, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Dave Anderson and William Thomsen Join SRI Internationals Center for Advanced Drug Research to Lead Programs in Proteomics and Metabolic Disease Drug Discovery
2. TransTech Medical Solutions Expands Offering to MD Anderson Cancer Center to Include Outsourced Medical Transcription and Editing Services
3. Statement of Ben Anderson, Esq., Regarding Denial of Wyeths En Banc Petition to Sixth Circuit Court of Appeals in Major Drug Regulation Pre-emption Case
4. Researchers at MD Anderson Show That Positron Emission Mammography (PEM) Helps Evaluate Early Response to Neoadjuvant Chemotherapy
5. Frank Phillips, Paul Anderson and Federico Girardi Join SI-BONEs Medical Advisory Board
6. Stemline Therapeutics Expands Clinical Oncology Program Directed at Cancer Stem Cells With Addition of M.D. Anderson Cancer Center
7. NovaBay Pharmaceuticals Expands Management Team; Names Mark Anderson, Ph.D. as Chief Scientific Officer
8. Help is Here Express Arrives in Anderson, Seneca
9. HS-7 Document Regarding Research @ M. D. Anderson Orlando
10. M. D. Anderson to Initiate Clinical Validation Study on Rosetta Genomics MicroRNA-based Diagnostic Assay Identifying the Origin of Cancer Metastases
11. Rosetta Genomics and M. D. Anderson to Develop a MicroRNA-based Diagnostic Test to Identify Risk of Recurrence of Lung Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... , June 24, 2016   Pulmatrix, Inc ... company developing innovative inhaled drugs, announced today that it ... Russell Investments reconstituted its comprehensive set of U.S. ... "This is an important milestone for Pulmatrix," said ... increase shareholder awareness of our progress in developing drugs ...
(Date:6/23/2016)... -- Research and Markets has announced the addition ... 2022" report to their offering. ... with kidney failure, it replaces the function of kidneys by ... and thus the treatment helps to keep the patient body,s ... Increasing number of ESRD patients & substantial healthcare ...
(Date:6/23/2016)... 23, 2016 Roche (SIX: RO, ROG; OTCQX: ... its Elecsys BRAHMS PCT (procalcitonin) assay as a dedicated ... shock. With this clearance, Roche is the first IVD ... solution for sepsis risk assessment and management. ... and PCT levels in blood can aid clinicians in ...
Breaking Medicine Technology:
(Date:6/24/2016)... ... June 24, 2016 , ... Those who have experienced traumatic events ... turn to unhealthy avenues, such as drug or alcohol abuse, as a coping mechanism. ... tools for healthy coping following a traumatic event. , Trauma sufferers tend to feel ...
(Date:6/24/2016)... ... June 24, 2016 , ... Marcy was in a crisis. Her son James, eight, was out ... family verbally and physically. , “When something upset him, he couldn’t control his emotions,” remembers ... would throw rocks at my other children and say he was going to kill them. ...
(Date:6/24/2016)... ... June 24, 2016 , ... Global law firm Greenberg Traurig, P.A. announced that ... chosen by their peers for this recognition are considered among the top 2 percent ... special honors as members of this year’s Legal Elite Hall of Fame: Miami ...
(Date:6/24/2016)... ... 24, 2016 , ... Comfort Keepers® of San Diego, CA is excited to ... Recovery® program to drive cancer patients to and from their cancer treatments. Comfort ... quality of life and ongoing independence. Getting to and from medical treatments is ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... People across ... in Genome magazine’s Code Talker Award, an essay contest in which patients and their ... award to be presented at the 2016 National Society of Genetic Counselors (NSGC) Annual ...
Breaking Medicine News(10 mins):